The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stassen, M.
Right arrow Articles by Schmitt, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stassen, M.
Right arrow Articles by Schmitt, E.
The Journal of Immunology, 2000, 164: 5549-5555.
Copyright © 2000 by The American Association of Immunologists

Murine Bone Marrow-Derived Mast Cells as Potent Producers of IL-9: Costimulatory Function of IL-10 and kit Ligand in the Presence of IL-11

Michael Stassen*, Martina Arnold*, Lothar Hültner{dagger}, Christian Müller*, Christine Neudörfl*, Tanja Reineke* and Edgar Schmitt2,*

* Institute of Immunology, Johannes Gutenberg University, Mainz, Germany; and {dagger} GSF-National Research Center for Environment and Health, Institute of Experimental Hematology, München, Germany

Recently, the Th2-type cytokine IL-9 was identified by genetic mapping analyses as a key mediator that determines the susceptibility to asthma. This has been further supported by data from IL-9-transgenic mice in which the overexpression of IL-9 in the lung causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. In an accompanying paper, we demonstrate that murine bone marrow-derived mast cells (BMMC) after stimulation with either ionomycin, a combination of ionomycin and IL-1, or via IgE-Ag complexes and IL-1 are very potent producers of IL-9. Herein we show that a dramatic increase of IL-9 production is observed when BMMC activated with ionomycin/IL-1 or with IgE-Ag complexes/IL-1 are treated with either additional kit ligand (KL) or IL-10. Both KL and IL-10 considerably enhance the production of IL-9 mRNA and protein. We were also able to demonstrate that the production of endogenous IL-10 by activated mast cells acts on the production of IL-9. Half-life measurements of IL-9 mRNA revealed no significant effect by KL, but a 2-fold increase of mRNA stability under the influence of IL-10. Reporter gene assays of transfected BMMC showed an enhanced transcriptional activity of the IL-9 promoter in the presence of either IL-10 or KL compared with cells stimulated only with a combination of IL-1 and ionomycin. The influence of KL and IL-10 might be of physiological importance, because it is known that both cytokines are produced by bronchial epithelial cells.




This article has been cited by other articles:


Home page
 J. Leukoc. Biol.Home page
L. H. Ho, T. Ohno, K. Oboki, N. Kajiwara, H. Suto, M. Iikura, Y. Okayama, S. Akira, H. Saito, S. J. Galli, et al.
IL-33 induces IL-13 production by mouse mast cells independently of IgE-Fc{epsilon}RI signals
J. Leukoc. Biol., December 1, 2007; 82(6): 1481 - 1490.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. R. Hundley, A. M. Gilfillan, C. Tkaczyk, M. V. Andrade, D. D. Metcalfe, and M. A. Beaven
Kit and Fc{epsilon}RI mediate unique and convergent signals for release of inflammatory mediators from human mast cells
Blood, October 15, 2004; 104(8): 2410 - 2417.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C.-K. Yu and C.-L. Chen
Activation of Mast Cells Is Essential for Development of House Dust Mite Dermatophagoides farinae-Induced Allergic Airway Inflammation in Mice
J. Immunol., October 1, 2003; 171(7): 3808 - 3815.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
K. Honda, M. Arima, G. Cheng, S. Taki, H. Hirata, F. Eda, F. Fukushima, B. Yamaguchi, M. Hatano, T. Tokuhisa, et al.
Prostaglandin D2 Reinforces Th2 Type Inflammatory Responses of Airways to Low-dose Antigen through Bronchial Expression of Macrophage-derived Chemokine
J. Exp. Med., August 18, 2003; 198(4): 533 - 543.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
S. Nakae, Y. Komiyama, H. Yokoyama, A. Nambu, M. Umeda, M. Iwase, I. Homma, K. Sudo, R. Horai, M. Asano, et al.
IL-1 is required for allergen-specific Th2 cell activation and the development of airway hypersensitivity response
Int. Immunol., April 1, 2003; 15(4): 483 - 490.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
J. H. Von der Thusen, J. Kuiper, T. J. C. Van Berkel, and E. A. L. Biessen
Interleukins in Atherosclerosis: Molecular Pathways and Therapeutic Potential
Pharmacol. Rev., March 1, 2003; 55(1): 133 - 166.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
G. Cheng, M. Arima, K. Honda, H. Hirata, F. Eda, N. Yoshida, F. Fukushima, Y. Ishii, and T. Fukuda
Anti-Interleukin-9 Antibody Treatment Inhibits Airway Inflammation and Hyperreactivity in Mouse Asthma Model
Am. J. Respir. Crit. Care Med., August 1, 2002; 166(3): 409 - 416.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. Stassen, C. Muller, M. Arnold, L. Hultner, S. Klein-Hessling, C. Neudorfl, T. Reineke, E. Serfling, and E. Schmitt
IL-9 and IL-13 Production by Activated Mast Cells Is Strongly Enhanced in the Presence of Lipopolysaccharide: NF-{{kappa}}B Is Decisively Involved in the Expression of IL-9
J. Immunol., April 1, 2001; 166(7): 4391 - 4398.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2000 by The American Association of Immunologists, Inc. All rights reserved.